CTOs on the Move

RiboCor

www.ribocor.com

 
RiboCor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ribocor.com
  • 7077 Northland Cir N Ste 100
    Minneapolis, MN USA 55428
  • Phone: 763.746.3910

Executives

Name Title Contact Details

Similar Companies

Advanced Urgent Care

Advanced Urgent Care is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LifeMine Therapeutics

For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history. Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs. At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these into disruptively innovative medicines, and translational medical scientists bring the life-saving solutions forward into patients in need.

CELLINK

CELLINK is the first bioink company revolutionizing bioprinting. Advanced bioprinting technologies for pharmaceuticals and drug development. CELLINK is pioneering cell cultivation systems through bioprinting, analysis and liquid handling or bioprocessing.

Generation Bio

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.